A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure
Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare relative changes in blood N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels after 30 days of treatment in participants with worsening heart failure (WHF), who are treated with either OPC-131461 or placebo.
Phase:
PHASE2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.